{
    "clinical_study": {
        "@rank": "67048", 
        "arm_group": {
            "arm_group_label": "Treatment (lenalidomide, dexamethasone)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive lenalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies how well lenalidomide and dexamethasone work in treating\n      patients with relapsed or refractory multiple myeloma. Biological therapies, such as\n      lenalidomide, may stimulate the immune system in different ways and stop cancer cells from\n      growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop\n      the growth of cancer cells, either by killing the cells or by stopping them from dividing.\n      Giving lenalidomide together with dexamethasone may kill more cancer cells."
        }, 
        "brief_title": "Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma", 
        "condition": "Refractory Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To assess the confirmed response rate of the combination of lenalidomide (Revlimid\u00ae), and\n      dexamethasone in patients with relapsed myeloma who have previously become refractory to\n      lenalidomide or pomalidomide.\n\n      SECONDARY OBJECTIVES:\n\n      I. To assess the toxicity of the combination in patients with relapsed myeloma who have\n      previously received lenalidomide or pomalidomide.\n\n      II. To assess time to progression and overall survival.\n\n      OUTLINE:\n\n      Patients receive lenalidomide orally (PO) on days 1-21 and dexamethasone PO on days 1, 8,\n      15, and 22. Courses repeat every 28 days in the absence of disease progression or\n      unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up every 3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Calculated creatinine clearance >= 30 ml/min by Cockcroft-Gault formula\n\n          -  Absolute neutrophil count >= 1000\u03bcL\n\n          -  (Untransfused) platelet count >= 50000/\u03bcL\n\n          -  Hemoglobin >= 8.0 g/dL\n\n          -  Relapsed myeloma that previously became refractory to lenalidomide or pomalidomide,\n             after initial response of partial response or better to the drug; refractory is\n             defined as progression on treatment with a dose of at least 10 mg daily for\n             lenalidomide and 1 mg daily for pomalidomide; at least six months should have elapsed\n             since previous lenalidomide or pomalidomide therapy was stopped\n\n          -  Measurable disease of multiple myeloma as defined by at least ONE of the following:\n\n               -  Serum monoclonal protein >= 1.0 g/dL\n\n               -  >= 200 mg of monoclonal protein in the urine on 24 hour electrophoresis\n\n               -  Serum immunoglobulin free light chain >= 10 mg/dL AND abnormal serum\n                  immunoglobulin kappa to lambda free light chain ratio\n\n               -  Monoclonal bone marrow plasmacytosis >= 30% (evaluable disease)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2\n\n          -  Previously treated; NOTE: No limit to prior therapy provided there is adequate\n             residual organ function\n\n          -  Provide informed written consent\n\n          -  Females of childbearing potential (FCBP) must have a negative serum pregnancy test\n             with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again\n             within 24 hours prior to prescribing lenalidomide for cycle 1 (prescriptions must be\n             filled within 7 days as required by RevAssist), and must either commit to continued\n             abstinence from heterosexual intercourse or begin TWO acceptable methods of birth\n             control, one highly effective method and one additional effective method AT THE SAME\n             TIME, at least 28 days before she starts taking lenalidomide; FCBP must also agree to\n             ongoing pregnancy testing; men must agree to use a latex condom during sexual contact\n             with a FCBP even if they have had a successful vasectomy; all study participants must\n             be registered into the RevAssist\u00ae program, and be willing and able to comply with the\n             requirements of RevAssist\u00ae mandatory Rev; a female of childbearing potential is a\n             sexually mature woman who: 1) has not undergone a hysterectomy or bilateral\n             oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive\n             months (i.e., has had menses at any time in the preceding 24 consecutive months)\n\n          -  Willing to return to Mayo Clinic enrolling institution for follow-up\n\n        Exclusion Criteria:\n\n          -  Residual toxicity of > grade 1 from prior therapy\n\n          -  Other active malignancy < 1 year prior to registration; EXCEPTIONS: Non-melanotic\n             skin cancer or carcinoma-in-situ of the cervix; NOTE: If there is a history of prior\n             malignancy, they must not be receiving other specific treatment for their cancer\n\n          -  Any of the following:\n\n               -  Pregnant women\n\n               -  Nursing women (lactating females must agree not to breast feed while taking\n                  lenalidomide)\n\n               -  This study involves an agent that may have genotoxic, mutagenic and teratogenic\n                  effects; men or women of childbearing potential who are unwilling to employ\n                  adequate contraception (condoms, diaphragm, birth control pills, injections,\n                  intrauterine device [IUD], or abstinence, etc.)\n\n          -  Other co-morbidity which would interfere with patient's ability to participate in\n             trial, e.g. uncontrolled infection, uncompensated heart or lung disease\n\n          -  Other concurrent chemotherapy, radiotherapy, or any ancillary therapy considered\n             investigational; NOTE: Bisphosphonates are considered to be supportive care rather\n             than therapy, and are thus allowed while on protocol treatment\n\n          -  New York Heart Association classification III or IV\n\n          -  Diagnosed active deep vein thrombosis (DVT) that has not been therapeutically\n             anticoagulated"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01794039", 
            "org_study_id": "MC1187", 
            "secondary_id": "NCI-2013-00412"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (lenalidomide, dexamethasone)", 
                "description": "Given PO", 
                "intervention_name": "lenalidomide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CC-5013", 
                    "IMiD-1", 
                    "Revlimid"
                ]
            }, 
            {
                "arm_group_label": "Treatment (lenalidomide, dexamethasone)", 
                "description": "Given PO", 
                "intervention_name": "dexamethasone", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Aeroseb-Dex", 
                    "Decaderm", 
                    "Decadron", 
                    "DM", 
                    "DXM"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Lenalidomide", 
                "Thalidomide", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 19, 2014", 
        "location": {
            "contact": {
                "email": "kumar.shaji@mayo.edu", 
                "last_name": "Shaji K. Kumar", 
                "phone": "507-538-7623"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic"
            }, 
            "investigator": {
                "last_name": "Shaji K. Kumar", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 2 Trial of Retreatment With Lenalidomide and Dexamethasone for Patients With Relapsed Myeloma", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Shaji Kumar", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.", 
            "measure": "Proportion of confirmed tumor responses defined to be a partial response or better noted as the objective status on two consecutive evaluations", 
            "safety_issue": "No", 
            "time_frame": "Up to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01794039"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Shaji K. Kumar, M.D.", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The distribution of time to progression will be estimated using the method of Kaplan-Meier.", 
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "Time from registration to the earliest date with documentation of disease progression, assessed up to 1 year"
            }, 
            {
                "description": "The distribution of survival time will be estimated using the method of Kaplan-Meier.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Time from registration to death due to any cause, assessed up to 1 year"
            }, 
            {
                "description": "Recorded and reported for each patient, and frequency tables will be reviewed to determine adverse event patterns.", 
                "measure": "Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after last day of study drug treatment"
            }
        ], 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}